MUC5AC and Keratoconjunctivitis sicca: Diquafosol is marketed under the product name Diquas®, which was launched in Japan at the end of 2010 as a drug for the treatment of dry eye with a novel mechanism of action involving the stimulation of tear and mucin secretion.